

Ref: FOI/GS/ID 5034

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

15 November 2018

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Urothelial Cell Cancer.

You asked:

1. Please indicate the number of metastatic or locally advanced Urothelial cancer patients treated by your Trust in the 3 months, July 2018 to September 2018 inclusive.

If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.

If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:

2. Of the metastatic or locally advanced Urothelial cancer patients treated by your Trust in the 3 months, July 2018 to September 2018 inclusive, please indicate the number treated with the following therapies.

If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:

Cisplatin (mono or combination therapy)

Carboplatin (mono or combination therapy)

Pembrolizumab (Keytruda)

Atezolizumab (Tecentriq)

3. If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred:

Trust response:

1. Please note - Due to the very small number of cases and in order to protect patient confidentiality the Trust has decided that further information be refused using the limitations available under Section 10 and Section 11 of the Data Protection Act 1998.

<p>Total number treated (Metastatic/locally advanced Urothelial patients)</p>	<p>If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:</p>
--	--

Total number of metastatic or locally advanced Urothelial cancer (UCC, transitional carcinoma, TCC) patients treated	<10	Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	

2.

Therapy	Total number treated (Metastatic/locally advanced Urothelial patients)	If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:	
		Total Urothelial Cancer patients (any stage)	
Cisplatin (mono or combination therapy)	0	Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	
Carboplatin (mono or combination therapy)	0	Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	
Pembrolizumab (Keytruda)	0	Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	
Atezolizumab (Tecentriq)	0	Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	

3. Not applicable.